Next Stage: New solutions in animal health and how CMC decides their success

Animal health is advancing on two fronts: new modalities including mAbs, mRNA, CGT, vaccines, long-acting injectables, tides, conjugates etc. and new care models built on telehealth, remote monitoring and at-home treatment. Both change what a product must deliver, and both raise the CMC bar.

This session unpacks the five decisions that make or break commercial success: manufacturability, scalability, stability and distribution, regulatory reproducibility, and supply chain readiness with a practical lens on why cost-of-goods is uniquely decisive in animal health, and why most failures happen after proof-of-concept, not before it.

Great science earns attention. Great CMC earns the market.